EGFR and non-small cell lung carcinoma: In a study conducted by Xu Q et al. (Spry et al., 2018), the addition of local ablation therapy to EGFR-TKI demonstrated a satisfactory survival benefit for patients with EGFR-mutated NSCLC who experienced oligoprogression during their first-line EGFR-TKI therapy (Jiang et al., 2019).